Stock Market News2 days SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich’s Ataxia Zacks
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich’s ataxia.
XSolid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich’s ataxia.
X